Eiger BioPharmaceuticals Inc logo

Eiger BioPharmaceuticals Inc (EIGR)

Market Closed
30 Sep, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
1. 73
0
0%
$
2.55M Market Cap
- P/E Ratio
0% Div Yield
136,274 Volume
-48.58 Eps
$ 1.725
Previous Close
Day Range
1.73 1.9
Year Range
1.73 16
Want to track EIGR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

EIGR closed Monday higher at $1.73, an increase of 0% from Friday's close, completing a monthly decrease of -9.21% or $0.17. Over the past 12 months, EIGR stock lost -9.21%.
EIGR is not paying dividends to its shareholders.
The last earnings report, released on Apr 07, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Eiger BioPharmaceuticals Inc has completed 2 stock splits, with the recent split occurring on Jan 08, 2024.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

EIGR Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.

Eiger BioPharmaceuticals Inc Dividends

EIGR is not paying dividends to its shareholders.

Eiger BioPharmaceuticals Inc Earnings

7 Apr 2025 Date
-
Cons. EPS
-
EPS
7 Nov 2024 Date
-
Cons. EPS
-
EPS
12 Aug 2024 Date
-
Cons. EPS
-
EPS
27 Mar 2024 Date
-
Cons. EPS
-
EPS
25 Mar 2024 Date
-
Cons. EPS
-
EPS
EIGR is not paying dividends to its shareholders.
7 Apr 2025 Date
-
Cons. EPS
-
EPS
7 Nov 2024 Date
-
Cons. EPS
-
EPS
12 Aug 2024 Date
-
Cons. EPS
-
EPS
27 Mar 2024 Date
-
Cons. EPS
-
EPS
25 Mar 2024 Date
-
Cons. EPS
-
EPS

Eiger BioPharmaceuticals Inc (EIGR) FAQ

What is the stock price today?

The current price is $1.73.

On which exchange is it traded?

Eiger BioPharmaceuticals Inc is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is EIGR.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 2.55M.

Has Eiger BioPharmaceuticals Inc ever had a stock split?

Eiger BioPharmaceuticals Inc had 2 splits and the recent split was on Jan 08, 2024.

Eiger BioPharmaceuticals Inc Profile

Biotechnology Industry
Healthcare Sector
David Apelian CEO
NASDAQ (NMS) Exchange
28249U105 Cusip
US Country
56 Employees
- Last Dividend
8 Jan 2024 Last Split
30 Jan 2014 IPO Date

Overview

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of novel therapies for rare and ultra-rare diseases. Operating both within the United States and internationally, the company is driven by a mission to address unmet medical needs in conditions that are often overlooked. Founded in 2008 and based in Palo Alto, California, Eiger BioPharmaceuticals has established itself as a key player in the realm of rare disease therapy development.

Products and Services

The company's product pipeline is diverse and focused on targeted therapies that promise to provide significant clinical benefits for patients suffering from rare diseases. These include:

  • Lonafarnib: This lead product candidate is a testament to Eiger BioPharmaceuticals' innovative approach in tackling rare diseases. As an orally bioavailable, small molecule, Lonafarnib is currently in Phase III clinical trials for the treatment of hepatitis delta virus infection. This showcases the company's commitment to addressing infectious diseases with limited treatment options.
  • Lambda: Another significant product in Eiger's portfolio, Lambda is designed to target type III interferon receptors. Having completed Phase II clinical trials, Lambda represents the company's pursuit of new therapeutic pathways for treating diseases at a cellular receptor level, showing promise in the pharmacological landscape.
  • Lonafarnib for Progeria and Progeroid Laminopathies: Expanding the application of Lonafarnib, Eiger is exploring its use in treating progeria and progeroid laminopathies. This rare, yet severe, genetic conditions accelerate aging in children, highlighting the company's focus on pediatric rare diseases and its dedication to extending lifespans and improving quality of life.
  • Avexitide for Congenital Hyperinsulinism and Post-Bariatric Hypoglycemia: Avexitide represents Eiger's foray into metabolic disorders, with its application in treating congenital hyperinsulinism. Moreover, Avexitide has completed Phase II clinical trials to address post-bariatric hypoglycemia, underscoring Eiger's versatility in developing drugs for a broad spectrum of rare conditions.

Contact Information

Address: 2155 Park Boulevard
Phone: 650 272 6138